<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (eNOS) activity is decreased after <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="9150">Simvastatin</z:chebi> increases eNOS activity </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that <z:chebi fb="0" ids="9150">simvastatin</z:chebi> would increase eNOS protein and ameliorate SAH-induced <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Mice were treated with subcutaneous <z:chebi fb="0" ids="9150">simvastatin</z:chebi> or vehicle for 14 days and then subjected to endovascular <z:mpath ids='MPATH_81'>perforation</z:mpath> of the right anterior cerebral artery or sham surgery </plain></SENT>
<SENT sid="4" pm="."><plain>Three days later, neurological deficits were scored (5 to 27; 27=<z:mpath ids='MPATH_458'>normal</z:mpath>), and middle cerebral artery diameter and eNOS protein were measured </plain></SENT>
<SENT sid="5" pm="."><plain>The study was repeated, but <z:chebi fb="0" ids="9150">simvastatin</z:chebi> treatment was started after SAH or sham surgery </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In SAH mice, <z:chebi fb="0" ids="9150">simvastatin</z:chebi> pretreatment increased middle cerebral artery diameter (SAH-<z:chebi fb="0" ids="9150">simvastatin</z:chebi>=74+/-22 micro m, SAH-vehicle=52+/-18 micro m, P=0.03; sham-<z:chebi fb="0" ids="9150">simvastatin</z:chebi>=102+/-8 micro m, sham-vehicle=105+/-6 micro m) </plain></SENT>
<SENT sid="7" pm="."><plain>Pretreatment reduced neurological deficits (SAH-<z:chebi fb="0" ids="9150">simvastatin</z:chebi>=25+/-2, SAH-vehicle=20+/-2, P=0.005; sham-<z:chebi fb="0" ids="9150">simvastatin</z:chebi> and sham-vehicle=27+/-0) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="9150">Simvastatin</z:chebi> pretreatment also increased eNOS protein </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="9150">Simvastatin</z:chebi> posttreatment caused a modest increase in middle cerebral artery diameter in SAH mice (SAH-<z:chebi fb="0" ids="9150">simvastatin</z:chebi>=56+/-12 micro m, SAH-vehicle=45+/-4 micro m, P=0.03; sham-<z:chebi fb="0" ids="9150">simvastatin</z:chebi>=92+/-13 micro m, sham-vehicle=99+/-10 micro m) and reduced neurological deficits (SAH-<z:chebi fb="0" ids="9150">simvastatin</z:chebi>=21+/-1, SAH-vehicle=19+/-2, P=0.009) </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="9150">Simvastatin</z:chebi> posttreatment did not significantly increase eNOS protein </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="9150">Simvastatin</z:chebi> treatment before or after SAH attenuated <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and neurological deficits in mice </plain></SENT>
<SENT sid="12" pm="."><plain>The mechanism may be attributable in part to eNOS upregulation </plain></SENT>
</text></document>